Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)
Savara (SVRA) posted quarterly Net Income towards Common Stockholders of -$37.3 million for Q1 2026, down 39.96% year-over-year from -$62.1 million in Q1 2025, and down 15.66% quarter-over-quarter from -$32.2 million in Q4 2025.
Analysis
Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$37.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million; the TTM figure through Mar 2026 stood at -$129.5 million (down 26.73% YoY), while the FY2025 annual figure was -$118.8 million, down 23.94% from the prior year.
- Net Income towards Common Stockholders retreated to -$37.3 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$8.3 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$20.3 million across 5 years, with a median of -$20.3 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders advanced 18.76% — and 2024, when it sank 94.38%.
- Savara's Net Income towards Common Stockholders stood at -$10.3 million in 2022, then tumbled by 56.3% to -$16.1 million in 2023, then slumped by 80.41% to -$29.0 million in 2024, then slipped by 10.99% to -$32.2 million in 2025, then decreased by 15.66% to -$37.3 million in 2026.
- Business Quant data shows SVRA's Net Income towards Common Stockholders at -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | -40.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.23 Mn |
| Mar 31, 2026 | -37.28 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -30.40 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.04 Mn |
| Sep 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -22.24 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.10 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.39 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -10.55 Mn |